These findings suggest that higher TRA16 expression is associated with reduced infiltration of both stromal and immune components, indicating that TRA16 may be preferentially expressed in tumor-cell–dominant regions with a less prominent microenvironmental presence. The gene discussed is NR2C2AP; the disease is neoplasm.